publication . Article . 2018

Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation

Marco Bellone; Lorenzo Pradelli; Mario Bo;
Open Access English
  • Published: 27 Feb 2018 Journal: Farmeconomia. Health economics and therapeutic pathways (issn: 2240-256X, eissn: 2240-256X, Copyright policy)
  • Publisher: SEEd Medical Publishers
Abstract
<jats:p>INTRODUCTION: The direct oral anticoagulants (DOACs) have demonstrated a more predictable effect and a more favorable risk-benefit ratio compared to the standard oral anticoagulant treatment for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF).AIM: To estimate the efficiency of DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban vs. warfarin), in the prevention of clinical events in adult patients with NVAF.METHODS: A deterministic incremental cost-effectiveness analysis was performed to evaluate the avoidance of a clinical event and the incremental cost per avoided clinical event, in a hypothetical population of 100,0...
Subjects
free text keywords: Direct oral anticoagulants; Thromboembolic events; Non-valvular atrial fibrillation, direct oral anticoagulants, thromboembolic events, non-valvular atrial fibrillation, Medicine (General), R5-920, Apixaban, medicine.drug, medicine, Relative risk, Emergency medicine, medicine.medical_specialty, business.industry, business, Stroke, medicine.disease, Warfarin, Dabigatran, Population, education.field_of_study, education, Rivaroxaban, Edoxaban, chemistry.chemical_compound, chemistry
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2018

Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation

Marco Bellone; Lorenzo Pradelli; Mario Bo;